Recently, the US Food and Drug Administration (FDA) approved Lynparza (Olapali) for the treatment of metastatic breast cancer carrying the germline BRCA gene mutation (gBRCAm) and human epidermal growth factor receptor 2 (HER2) negative. Patient. This is the third indication that Olapali was approved in the United States. In the United States, Olapali has been used […]
